Amidst an unprecedented fall in the EBITDA margins of Fortis, whether its two bidders can revive the company's operations is a million dollar question.
Missed your morning newspaper? Rushing to get to office? ThePrint has the daily news covered for you. From national headlines to opinions and business news, this is all that India's papers are reporting today.
The founders had taken at least 5 billion rupees of Fortis Healthcare’s cash without board approval. The market regulator, and India’s Serious Fraud Investigation Office, are looking into the company and auditors have refused to certify financial results.
Fortis is discussing issuing around 40 billion rupees ($615 million) of new stock to TPG and Manipal through a preferential allotment, one of the people said.
Assam CM can’t celebrate that the Congress drew a blank in the Bodoland Territorial Council polls in 2010 as well as 2015, and bagged only one in 2020.
SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.
In post on social media, Cooper narrated experience of MiG-21 researcher from Germany who wanted to attend aircraft’s farewell ceremony in India, and the roadblocks he faced.
What Munir has achieved with Trump is a return to normal, ironing out the post-Abbottabad crease. The White House picture gives us insight into how Pakistan survives, occasionally thrives and thinks.
Ranbaxy, once one of India’s most trusted brands in pharmaceuticals, proved a lemon for its Japanese buyers, Dai ichi, who sold it later to Sun Pharmaceuticals. There was a lot of fudging in that transaction, for which the Brothers Singh are still trying to wriggle out of responsibility. They would have prospered more if they had practised a higher standard of corporate governance.
I fail to understand why an insurance is necessary at all. If I am sick I go to a doctor and pay his charges. Cut the Insurance Co to its size.
Ranbaxy, once one of India’s most trusted brands in pharmaceuticals, proved a lemon for its Japanese buyers, Dai ichi, who sold it later to Sun Pharmaceuticals. There was a lot of fudging in that transaction, for which the Brothers Singh are still trying to wriggle out of responsibility. They would have prospered more if they had practised a higher standard of corporate governance.